MEDCO RESEARCH INC. – Trademark Portfolio

Entity Type: 03

MEDCO RESEARCH INC. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include BIDIL and ADENOCARD. The owner is based in LOS ANGELES, CA.

8733 BEVERLY BOULEVARD

LOS ANGELES, CA 90048

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

MEDCO RESEARCH INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (10 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does MEDCO RESEARCH INC. have?

MEDCO RESEARCH INC. has 12 U.S. trademarks filed with the USPTO. Of these, 2 registered, 8 abandoned, 2 cancelled.

What trademark classes does MEDCO RESEARCH INC. file in?

MEDCO RESEARCH INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are MEDCO RESEARCH INC.'s most well-known trademarks?

MEDCO RESEARCH INC.'s registered trademark portfolio includes well-known marks such as BIDIL and ADENOCARD. These are among 2 currently registered trademarks in the portfolio.

What is MEDCO RESEARCH INC.'s trademark registration success rate?

MEDCO RESEARCH INC. has a 17% trademark registration rate, with 2 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.